Analyst CommentFirst stock in the clip. 81% of analysts have this as a Buy with the concensus target being $3.24. Even the lowest target (Mackie at $2.10) is nearly 30% higher than where we currently sit. GLTA
https://www.bnn.ca/Video/player.aspx?vid=895853
MSL-T 2016-06-20 HOLD James Telfser
Buys older legacy drugs that big Pharma companies don’t want anymore. Generally they are free cash flowing drugs. Mostly in Europe. The stock has been extremely weak, but he is not seeing any good reason why the stock has dropped from $2 down to $1.65. Fundamentals are still intact. Last quarter was okay.
Login to show your approval Login to show your disapproval / Be the first to comment
Price:
$1.640
Subject:
CANADIAN
Bias:
OPTIMISTIC
Owned:
Yes